Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | EDNRB | P24530 | 1/20 | 0.44 |
| ▸ | EDNRA | P25101 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29642916 | 1.00 | TP53 (0.59) | TP53MAPTLMNACYP1A2CYP3A4 | |
| Ethane SCHEMBL28466111 | 0.96 | MAPT (0.55) | TP53MAPTLMNACYP1A2CYP3A4 | |
| SCHEMBL3135177 | 0.87 | CYP1A2 (0.58) | TP53MAPTLMNACYP1A2CYP3A4 | |
| SCHEMBL25028023 | 0.79 | LMNA (0.54) | TP53MAPTLMNACYP1A2CYP3A4 | |
| SCHEMBL29370508 | 0.77 | LMNA (0.54) | TP53MAPTLMNACYP1A2CYP3A4 | |
| SCHEMBL70993 | 0.77 | LMNA (0.54) | TP53MAPTLMNACYP1A2CYP3A4 | |
| SCHEMBL25171318 | 0.77 | LMNA (0.54) | TP53MAPTLMNACYP1A2CYP3A4 | |
| SCHEMBL11099939 | 0.76 | ALDH1A1 (0.45) | TP53MAPTLMNACYP1A2CYP3A4 | |
| SCHEMBL11415624 | 0.76 | CYP19A1 (0.60) | TP53MAPTLMNACYP1A2CYP3A4 | |
| SCHEMBL11415626 | 0.76 | CYP19A1 (0.60) | TP53MAPTLMNACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109414452-B | Cyclodextrins as procoagulants | 阿弗隆制药有限公司 | 2024-02-02 | — | — | CN | claimed |
| CN-116829168-A | Use of cyclosporin analogs as antithrombotic agents | 海必恩制药公司 | 2023-09-29 | — | — | CN | claimed |
| CN-114728918-B | RIP1 inhibitory compounds and methods of making and using the same | 里格尔药品股份有限公司 | 2025-06-17 | — | — | CN | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| CN-113416254-B | Anti-C5 antibodies with improved pharmacokinetics | 瑞颂医药公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-115867548-B | RIP1K inhibitors | 里格尔药品股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-112996519-B | Compositions and methods for organ-specific delivery of nucleic acids | 德克萨斯大学系统董事会 | 2025-02-28 | — | — | CN | disclosed |
| CN-119421870-A | Lipid compound and application thereof | 传信生物医药(苏州)有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-119384273-A | Organ-specific delivery compositions for nucleic acids | 传信生物医药(苏州)有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-119219587-A | Method for preparing phthalide by oxidizing o-xylene | 中国石油化工股份有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-119039128-A | Hydroxy naphthoquinone compound for targeted inhibition of vitamin K epoxide reductase and application thereof | 哈尔滨医科大学 | 2024-11-29 | — | — | CN | disclosed |
| US-20160052982-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2016-02-25 | — | — | US | disclosed |
| US-7374580-B2 | Dyeing compositions comprising A 1,2-indandione derivative | L'OREAL S.A. (FR) | 2008-05-20 | — | — | US | disclosed |
| US-7374580-B2 | Dyeing compositions comprising A 1,2-indandione derivative | L'OREAL S.A. (FR) | 2008-05-20 | — | — | US | disclosed |
| US-20080095838-A1 | Solid pharmaceutical composition containing a lipophilic active principle and preparation method thereof | CLL PHARMA (FR) | 2008-04-24 | — | — | US | disclosed |
| CN-1329282-A | Photographic element with ion exchange compound | EASTMAN KODAK CO (US) | 2002-01-02 | — | — | CN | disclosed |
| US-4804684-A | ANTICONVULSANTS, ANALGESICS | PANMEDICA S.A. (FR) | 1989-02-14 | — | — | US | disclosed |
| EP-0236151-A1 | Symmetrically O-disubstituted oximes of benzocondensed beta-diketocycloalkenes, processes for their preparation and their use as medicaments | PANMEDICA S.A. (FR) | 1987-09-09 | — | — | EP | disclosed |
| EP-0178903-A2 | Improved tellurium imaging composition and film including imide or ammonium salt | ENERGY CONVERSION DEVICES, INC. (US) | 1986-04-23 | — | — | EP | disclosed |
| US-3954998-A | HERBICIDES | UNION CARBIDE CORPORATION (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052982-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | TP53 1522/4885MAPT 4449/4885LMNA 2571/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | TP53 1522/4885MAPT 4449/4885LMNA 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.